Ferring Bets Up to $1.38B on Gameto's Lab-Grown Ovarian Cells
- Ferring Pharmaceuticals has agreed to buy fertility startup Gameto, with total consideration of up to about $1.38 billion.
- Gameto builds products on iPSC-derived ovarian support cells, an approach to maturing eggs outside the body.
- Its lead product, Fertilo, is already cleared in several markets outside the US and is in a US Phase 3 trial, according to earlier company disclosures.
💡 Points
A $1.38B ceiling is a headline, not a price. With the upfront/milestone split undisclosed, the figure mostly shows how much value may hinge on Fertilo's US Phase 3. Buying while the pivotal trial is still running looks like a bid to own an iPSC-based IVF platform before the US read-out, not after.
Ferring to acquire ovary-in-a-dish startup Gameto for up to $1.38B ↗